Intraoperative arteriovenous patient sampling to assess in situ non-small cell lung cancer metabolism
Johnathan R. KentiD, Keene L. AbbottiD, Rachel K. NordgreniD, Amy DeikiD, Nupur Kanti DasiD, Millenia WaiteiD, Tenzin KunchokiD, Anna Shevzov-Zebrun, Nathaniel Christiansen, Amir Sadek, Darren S. BryaniD, Mark K. Ferguson, Jessica Scott DoningtoniD, Alexander MuiriD, Yatrik Madhukar ShahiD, Clary B. ClishiD, Matthew G. Vander HeideniD, Maria Lucia L. MadariagaiD, Peggy P. HsuiD
Abstract
We performed intraoperative arteriovenous sampling in participants undergoing surgical resection for non-small cell lung cancer (NSCLC) to characterize in situ tumor metabolism, directly measuring metabolite consumption and secretion in tumor-bearing lung versus normal lung and the systemic circulation. Healthy lung tissue secreted lower levels of lactate, pyruvate, and tricarboxylic acid (TCA) intermediates and consumed less glucose compared to the systemic circulation. In contrast, tumor-bearing lung demonstrated elevated lactate secretion, along with increased efflux of succinate, fumarate, glycine, and aspartate, despite similar glucose uptake. Lactate secretion correlated with tumor PET avidity but not size, and overall metabolic profiles distinguished cancerous from normal lung tissue. These findings confirm enhanced glycolysis in NSCLC in vivo, while also revealing context-dependent patterns of TCA metabolite accumulation and amino acid secretion. Our results demonstrate the utility of intraoperative sampling to uncover metabolic features of human tumors.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 4th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multimodal Analysis Reveals Differential Immuno-Metabolic Features in Lung Squamous Cell Carcinoma and Adenocarcinoma
B. P. Leitner, S. Ospanova, … R. J. Perry·bioRxiv·May 9, 2021
- MCT1 activity defines an aggressive metabolic phenotype and therapeutic target in non-small cell lung cancer
Robert B Cameron, Kristen Erika Shema, … Brandon Faubert·bioRxiv·Sep 22, 2026
- Divergent use of metabolic fluxes in breast cancer metastasis
- Metabolomic-based biomarker discovery for non-invasive lung cancer screening: A case study
Keiron O'Shea, Simon JS Cameron, … Luis AJ Mur·bioRxiv·Jul 12, 2016
- METABOLIC DIVERSITY IN HUMAN NON-SMALL CELL LUNG CANCER CELLS
P.-H. CHEN, L. Cai, … R. J. DeBerardinis·bioRxiv·Mar 11, 2019
- Optical imaging of treatment-naive human NSCLC reveals changes associated with metastatic recurrence
Paola Monterroso Díaz, Jesse D. Ivers, … Narasimhan Rajaram·bioRxiv·Oct 14, 2024